Compare IONQ Inc (IONQ) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? IONQ Inc trades at $39.43 (market cap $15.98B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 3.7× IONQ Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| IONQ | TAK | |
|---|---|---|
Market Cap | $15.98B | $58.74B |
Volume | 22,848,240 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $82.09 | $19.05 |
52-Week Low | $26.59 | $13.23 |
Enterprise Value | $13.92B | $86.65B |
Typical Hold Time | — | 1 Days |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.19, down 5.2% in the last session, with a bearish technical outlook despite recent positive analyst coverage. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a net income margin of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss following two consecutive beats. The stock remains 50% below analyst consensus price target of $62.75, indicating substantial upside potential if execution improves.
IONQ presents a high-risk, high-reward opportunity with Wall Street divided (50% buy, 50% hold). The bullish case hinges on quantum computing leadership and partnerships with major cloud providers, while risks include persistent losses, cash burn, and execution challenges in a nascent market. Current valuation metrics (P/S: 54.74) reflect growth expectations rather than current fundamentals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
